title: Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population.
abstract: This study assessed and described the episode rate, duration of illness, and health care utilization and costs associated with acute gastroenteritis (AGE), norovirus gastroenteritis (NVGE), and rotavirus gastroenteritis (RVGE) in physician office, emergency department (ED), and inpatient care settings in the United States (US). The retrospective analysis was conducted using an administrative insurance claims database (2006-2011). AGE episode rates were assessed using medical (ICD-9-CM) codes for AGE; whereas a previously published "indirect" method was used in assessing estimated episode rates of NVGE and RVGE. We calculated per-patient, per-episode and total costs incurred in three care settings for the three diseases over five seasons. For each season, we extrapolated the total economic burden associated with the diseases to the US population. The overall AGE episode rate in the physician office care setting declined by 15% during the study period; whereas the AGE episode rate remained stable in the inpatient care setting. AGE-related total costs (inflation-adjusted) per 100 000 plan members increased by 28% during the 2010-2011 season, compared with the 2006-2007 season ($832,849 vs. $1 068 116) primarily due to increase in AGE-related inpatient costs. On average, the duration of illness for NVGE and RVGE was 1 day longer than the duration of illness for AGE (mean: 2 days). Nationally, the average AGE-related estimated total cost was $3.88 billion; NVGE and RVGE each accounted for 7% of this total. The episodes of RVGE among pediatric populations have declined; however, NVGE, RVGE and AGE continue to pose a substantial burden among managed care enrollees. In conclusion, the study further reaffirms that RVGE has continued to decline in pediatric population post-launch of the rotavirus vaccination program and provides RVGE- and NVGE-related costs and utilization estimates which can serve as a resource for researchers and policy makers to conduct cost-effectiveness studies for prevention programs.
authors.affiliation: RTI Health Solutions; Research Triangle Park, NC USA.
authors.forename: Sudeep
authors.initials: S
authors.lastname: Karve
authors.affiliation: GlaxoSmithKline;King of Prussia, PA USA.
authors.forename: Girishanthy
authors.initials: G
authors.lastname: Krishnarajah
authors.affiliation: RTI Health Solutions; Research Triangle Park, NC USA.
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Korsnes
authors.affiliation: GlaxoSmithKline Vaccines; Wavre, Belgium.
authors.forename: Adrian
authors.initials: A
authors.lastname: Cassidy
authors.affiliation: RTI Health Solutions; Research Triangle Park, NC USA.
authors.forename: Sean D
authors.initials: SD
authors.lastname: Candrilli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017250:Caliciviridae Infections / Q000191:economics / Q000453:epidemiology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D005260:Female; D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology* / Q000473:pathology; D006268:Health Facilities / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008329:Managed Care Programs; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology* / Q000473:pathology; D014481:United States / Q000453:epidemiology; D055815:Young Adult
keywords: acute gastroenteritis; duration of illness; health care cost; norovirus; rotavirus
references.citation: N Engl J Med. 2013 Mar 21;368(12):1121-30
references.pmid: 23514289
references.citation: Emerg Infect Dis. 2011 Aug;17(8):1381-8
references.pmid: 21801613
references.citation: MMWR Morb Mortal Wkly Rep. 2007 Aug 24;56(33):842-6
references.pmid: 17717513
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):466-74
references.pmid: 21258098
references.citation: J Infect Dis. 2011 Oct 1;204(7):980-6
references.pmid: 21878425
references.citation: Nat Med. 2013 Sep;19(9):1076-7
references.pmid: 24013733
references.citation: Clin Infect Dis. 2011 Aug 1;53(3):245-53
references.pmid: 21705316
references.citation: MMWR Morb Mortal Wkly Rep. 2009 Oct 23;58(41):1146-9
references.pmid: 19847149
references.citation: MMWR Recomm Rep. 2009 Feb 6;58(RR-2):1-25
references.pmid: 19194371
references.citation: Clin Infect Dis. 2013 Mar;56(6):755-60
references.pmid: 23349228
references.citation: Hum Vaccin. 2011 May;7(5):563-8
references.pmid: 21441783
references.citation: Clin Infect Dis. 2011 Sep;53(6):568-71
references.pmid: 21832262
references.citation: Clin Infect Dis. 2012 Aug;55(4):e28-34
references.pmid: 22543022
references.citation: Med J Aust. 2012 Oct 15;197(8):453-7
references.pmid: 23072242
references.citation: Epidemiol Infect. 2007 Feb;135(2):293-301
references.pmid: 17291364
references.citation: BMJ. 2012 Aug 08;345:e4752
references.pmid: 22875947
references.citation: Pediatrics. 2010 Feb;125(2):e208-13
references.pmid: 20100757
references.citation: Hum Vaccin Immunother. 2012 Oct;8(10):1407-15
references.pmid: 22960495
references.citation: N Engl J Med. 2011 Sep 22;365(12):1108-17
references.pmid: 21992123
references.citation: Expert Rev Vaccines. 2009 Dec;8(12):1627-41
references.pmid: 19943758
references.citation: BMC Infect Dis. 2013 Mar 01;13:112
references.pmid: 23452879